24 / 32
Page 64
Notes:
allied
academies
Nov 22-23, 2018 | Paris, France
Joint Event
Nutrition and Health
16
th
International Conference on
26
th
International Conference on
Diabetes and Endocrinology
&
Journal of Insights in Nutrition and Metabolism | Volume 2
Recent updates on glucokinase activators and glucokinase regulatory protein disrupters for the
treatment of type 2 diabetes mellitus
Aditi Kaushik
IK Gujrat Punjab Technical University, India
T
he impairment of glucose metabolism leads to
hyperglycemia and type 2 diabetes mellitus. Glucokinase
enzyme is the key regulator of glucose homeostasis that
catalyzes the conversion of glucose to glucose-6-phosphate
in liver and pancreatic cells. In hepatocytes, GK controls the
glucose uptake and glycogen synthesis. The action of liver
GK is controlled by glucokinase regulatory protein (GKRP)
partially. In fasting conditions, the GKRP binds with GK and
inactivate it from carbohydrate metabolism and serve as
new target for treatment of diabetes mellitus. However, the
GK activators as potential antidiabetic agents but results in
increased risks of hypoglycemia. The allosteric inhibitors of
the GK-GKRP interaction are coming as alternative agents that
can mitigate the risk associated with GK activators. This review
discusses the recent advances and current status of potential
molecules targeted to GK activators and GK-GKRP disrupters
e:
aditikaushik2006@gmail.com